The global stem cell market is estimated to be worth USD 52124 million by 2032 and USD 20430 million in 2024, growing at a CAGR of 12.42% during the forecast period. The market is to increase because of the extensive research and development, which is gaining significant importance.
In multicellular organisms, stem cells have a unique ability to regenerate into a specific cell to form different tissues in the body. These cells can work as a replacement in place of damaged tissue cells and have full applications in healthcare and as a result, stem cells have been accepted throughout the world. Regenerative medicine is possibly the most important use of stem cells and other essential areas comprise cardiology, neurology, orthopedics, hematology and oncology. Drug discovery is another application where stem cells have been increasingly used. Stem cells are used as a research tool by researchers in vitro studies to deeply understand the role of various organs and the development of diseases. Stem cell therapy has shown significant potential to treat cancer successfully.
The cancer patient population is on the rise worldwide and is expected to fuel in the coming years. WHO says cancer is the second leading cause of death globally and caused an estimated 9.6 million deaths in 2018. The American Cancer Society predicts that there were an estimated 1.9 million new cancer cases in the U.S. were recorded in 2022. The usage of stem cells in cancer treatments has seen a tremendous spike in recent years and this trend is expected to continue in the coming years as stem cells hold great promise to treat cancer. Considering the potential of stem cells such as regenerating damaged tissues and replacing cancerous cells, the demand for stem cells has been increasing steadily over the last few years.
The potential that stem cells hold in treating various diseases has been recognized in recent years and several pharmaceutical companies have been conducting numerous R&D activities to explore the possibilities of stem cells and this trend is likely to continue during the forecast period and contribute to the market growth. For Instance, somatic stem cell therapy or bone marrow transplant is a procedure used to treat leukemia (blood cancer) as bone marrow has many stem cells.
The aging population is on the rise worldwide and as per the estimates of the United Nations (UN), 1 in every 6 people is predicted to be aged above 65 years by 2050 and the total population above 65 years will reach 1.5 billion by 2050. People are much more likely to experience age-related diseases and conditions such as arthritis, cardiovascular diseases, and neurodegenerative disorders with growing age. Stem cell therapies can treat these conditions by regenerating damaged tissues and organs and this awareness among the healthcare professionals and patient population has increased notably in recent years and boosted the demand levels for stem cells. The regenerative capacity of a human body gradually decreases with growing age and in such situations, stem cell therapies can be used to address age-related health issues such as age-related macular degeneration, osteoporosis and Alzheimer's disease. People who are aged have higher chances of organ failure and require organ transplantation. The world is currently facing a severe shortage of organ donors. Some healthcare organizations have been using stem cell-based therapies for organ regeneration as stem cells generate new tissues and organs that can eliminate the need for organ transplantation.
The growing investments by the governments and market participants for the R&D of stem cells, increasing technological advancements, rising awareness regarding the potential benefits of stem cells among healthcare professionals and increasing number of collaborations between the market participants and academic institutions to explore the possibilities of stem cells contribute to the market’s growth rate. The favorable regulations and initiatives by the governments for stem cells, rising demand for regenerative medicine, growing patient population suffering from orthopedic diseases, rising adoption of personalized medicine and growing use of stem cells in drug discovery and development further support the stem cell market growth. The rising demand for stem cell banking services, growing adoption of stem cell therapies in developing countries, increasing number of stem cell clinical trials, technological advancements in stem cell processing and preservation, rising use of stem cells in tissue engineering and growing demand for stem cell-based therapies in veterinary medicine are anticipated to fuel the growth rate of the stem cell market during the forecast period.
Lack of standardization in stem cell research and therapy and limited availability of stem cells further hinder market growth. Unfavorable reimbursement policies for stem cell therapies in some countries, stringent regulatory environment for stem cell research and therapy in some countries, safety and efficacy issues of stem cell therapy and the competition from alternative therapies such as gene therapy and immunotherapy further impede the market growth.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Covered |
By Treatment Mode, Cell Type, Technology Segment, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
Athersys, StemCells, Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences, Inc., Celgene Corporation, Invitrogen, and Cytori Therapeutics Inc. |
The allogeneic segment had the largest share of the global market in 2023 and the segmental domination is expected to continue during the forecast period. The advancements in stem cell research such as effective methods of harvesting, processing and storing allogeneic stem cells, the shortage of donor stem cells and the rising demand for regenerative medicine boost segmental growth. The rising support and funding from several governments for stem cell research and therapy and the increasing number of regulatory approvals for allogeneic stem cell therapy further drive segmental growth.
On the other hand, the autologous segment is predicted to register a promising CAGR in the coming years due to factors such as the growing usage of autologous stem cell therapy for chronic disease patient population and rising awareness among the patient population regarding the benefits of autologous stem cell therapy.
The adult stem cell segment held the leading share of the global market in 2023 and is expected to showcase a healthy CAGR during the forecast period. The growing prevalence of chronic diseases, increasing geriatric population worldwide and rising emphasis on research and development of new therapies based on adult stem cells majorly propel the segmental growth.
The induced pluripotent stem cells segment accounted for the second-largest share of the worldwide market in 2023 and is anticipated to grow at the highest CAGR during the forecast period. The rising demand for personalized medicine, the increasing incidence of chronic diseases, the growing focus on research and development of new therapies based on iPSCs and the increasing availability of funding for stem cell research primarily contribute to the segmental growth.
The human embryonic stem cell segment is anticipated to register a steady CAGR during the forecast period owing to the rising emphasis on research and development of new therapies based on hESCs and the growing demand for organ transplantation.
The cell acquisition segment had the leading share of the global market in 2023 and is expected to witness notable growth during the forecast period. The growth of the segment is majorly driven by the growing prevalence of chronic diseases, the increasing geriatric population, the rising demand for stem cell therapies and the technological advancements in stem cell isolation and collection techniques.
The cell production segment is a lucrative segment is expected to register the fastest CAGR during the forecast period due to factors such as the growing demand for regenerative medicine, the rising focus on personalized medicine, the development of new stem cell-based therapies and the increasing availability of funding for stem cell research.
The cryopreservation segment is estimated to showcase steady growth during the forecast period. Factors such as the rising demand for stem cell banking, the increasing focus on regenerative medicine, the development of new therapies based on stem cells and technological advancements in cryopreservation techniques majorly support the segmental growth.
The North American region held the largest share of the worldwide market in 2023 and the domination of the North American region in the worldwide market is expected to continue throughout the forecast period. The growing prevalence of chronic diseases, rising geriatric population and the growing demand for regenerative medicine in North America majorly propel the North American market growth. The presence of established healthcare infrastructure, technological advancements and favorable government initiatives further contribute to the growth rate of the North American market. The increasing availability of funding for stem cell research, high disposable income, growing healthcare expenditure, increasing number of partnerships and collaborations between industry players and research institutions and growing demand for stem cell-based therapies for the treatment of chronic diseases are anticipated to boost the growth rate of the North American market growth during the forecast period. The National Institute of Health (NIH) has been offering substantial funding support for stem cell research in the U.S. since 2016. The U.S. held the major share of the North American market followed by Canada in 2022 and the same trend is expected to continue throughout the forecast period. Factors such as the growing demand for regenerative medicine and the presence of well-established research and academic institutions majorly drive the U.S. market growth. California is one of the states to watch out for stem cell research. The California Institute for Regenerative Medicine (CIRM) funds stem cell research and clinical trials activities in California.
Europe captured a substantial share of the global market in 2023 and is expected to grow promisingly during the forecast period. The presence of several stem cell research centers and academic institutions, a rising emphasis on regenerative medicine and tissue engineering, a favorable regulatory environment, and supportive government initiatives primarily drive the growth of the European stem cell market. The European Union (EU) funded the Innovative Medicines Initiative (IMI) to support the research around stem cells and regenerative medicine in 2020. An increasing number of investments by private organizations in the stem cell industry of Europe, growing awareness and acceptance of stem cell therapy among patients and the rising prevalence of chronic diseases and the aging population further boost the growth rate of the European market. Germany occupied the major share of the European market in 2023 and the German market is expected to grow at a notable CAGR during the forecast period owing to factors such as the presence of well-established research and academic institutions and a supportive regulatory environment in Germany.
However, the APAC region is expected to grow at the fastest CAGR during the forecast period. The growth of the APAC market is primarily driven by factors such as the rapidly growing biotech and pharmaceutical industry, rising patient pool and increasing demand for stem cell-based therapies, favorable government policies and supportive regulatory environment for stem cell research. The large and diverse population base that provides a wide range of stem cell sources for research and therapy, growing investments in stem cell research and development by both governmental and private organizations, advancements in healthcare infrastructure and increasing healthcare expenditure further promote the growth rate of the APAC market. Japan captured the major share of the APAC market in 2023. The Japanese market is also predicted to register promising growth during the forecast period owing to factors such as the presence of a well-developed healthcare system, favorable regulatory environment, and government support for stem cell research. The Chinese stem cell market accounted for a considerable share of the APAC market in 2023 due to the growing number of clinical trials for stem cell-based therapies. The Indian stem cell market is estimated to register a lucrative CAGR during the forecast period owing to the presence of several companies and research institutions engaged in stem cell research and therapy. South Korea is projected to hold a considerable share of the APAC market during the forecast period.
The Latin American region is an emerging regional market for stem cells and is predicted to grow at a healthy CAGR during the forecast period due to the growing prevalence of chronic diseases, rising emphasis on regenerative medicine and stem cell therapy, growing healthcare expenditure, improving healthcare infrastructure, favorable regulatory environment and supportive government initiatives for stem cell research and growing awareness and acceptance of stem cell therapy among patients. Brazil and Mexico accounted for the major share of the Latin American market in 2023.
The market in the Middle East and Africa is forecasted to grow at a steady CAGR during the forecast period. The growing focus on stem cell therapy for the treatment of genetic disorders and rare diseases and rising awareness and acceptance of stem cell therapy among patients majorly boosts regional market growth. Israel and South Africa are predicted to account for the major share of the MEA market during the forecast period.
Some of the notable companies that are profiled in the global stem cell market are Athersys, StemCells, Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences, Inc., Celgene Corporation, Invitrogen, and Cytori Therapeutics Inc.
By Treatment Mode
By Cell Type
By Technology
By Region
Frequently Asked Questions
For the coming period of 2024 to 2029, the global stem cell market is expected to grow at a CAGR of 12.42%
Athersys, StemCells, Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences, Inc., Celgene Corporation, Invitrogen, and Cytori Therapeutics Inc. are some of the notable companies in the global stem cell market.
As per our report, the global stem cell market size is predicted to be worth USD 52124 million by 2032.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region